4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Rocuronium Bromide: new trials by email Literature Review of Rocuronium Bromide trials Research Report on Rocuronium Bromide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery BX1000, Rocuronium Bromide - Neuromuscular Blockade, Anesthesia | Phase 2 | Completed | Baudax Bio | 80 | 2022-10-25 | 2023-08-01 |
| Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042) MK-8616, Zemuron® - Neuromuscular Blockade | Phase 2 | Completed | Merck Sharp & Dohme LLC | 50 | 2004-08-01 | 2019-01-31 |
| Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) Sugammadex, Placebo, Esmeron® - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 174 | 2004-03-04 | 2019-02-11 |
| Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020). Placebo, Sugammadex, Esmeron® - Neuromuscular Blockade | Phase 2 | Completed | Merck Sharp & Dohme LLC | 99 | 2002-12-01 | 2019-04-02 |
Merck Sharp & Dohme LLC (3) · Baudax Bio (1)
United States (1)